Glaukos Corp. Company Profile (NYSE:GKOS)

Analyst Ratings

Consensus Ratings for Glaukos Corp. (NYSE:GKOS) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $30.40 (10.88% downside)

Analysts' Ratings History for Glaukos Corp. (NYSE:GKOS)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2016Cantor FitzgeraldInitiated CoverageNot Available -> Buy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/4/2016Roth CapitalBoost Price TargetBuy$24.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/8/2016Stifel NicolausInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/2/2016JPMorgan Chase & Co.Lower Price TargetOverweight$32.00 -> $28.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/19/2015William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/27/2015Goldman Sachs Group Inc.Lower Price Target$33.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Bank of America Corp.Initiated CoverageBuy$37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/20/2015Canaccord GenuityInitiated CoverageBuy$35.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Glaukos Corp. (NYSE:GKOS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/3/2016Q116($0.15)$0.03$18.77 million$23.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.13)($0.07)$20.07 million$20.28 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.17)($0.07)$17.93 million$19.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Glaukos Corp. (NYSE:GKOS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Glaukos Corp. (NYSE:GKOS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Glaukos Corp. (NYSE:GKOS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/13/2016Thomas William BurnsCEOSell162,254$30.07$4,878,977.78View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2016Richard L HarrisonCFOSell5,700$30.00$171,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Richard L HarrisonCFOSell4,300$30.00$129,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2016Thomas William BurnsCEOSell7,997$30.00$239,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2016Chris M CalcaterraInsiderSell45,464$28.46$1,293,905.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016Thomas William BurnsCEOSell24,578$25.16$618,382.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2016Thomas William BurnsCEOSell422$25.00$10,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2016Thomas William BurnsCEOSell25,000$23.90$597,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/25/2016Thomas William BurnsCEOSell300$25.00$7,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Chris M CalcaterraInsiderSell74,536$24.40$1,818,678.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Richard L HarrisonCFOSell30,000$24.59$737,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Thomas William BurnsCEOSell36,700$24.67$905,389.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/4/2016Aimee S WeisnerDirectorBuy2,500$16.03$40,075.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2016Montreux Equity Partners Iv LpMajor ShareholderSell70,000$16.16$1,131,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2015Richard L HarrisonCFOBuy1,388$15.30$21,236.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2015Aimee S WeisnerDirectorBuy2,500$21.83$54,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Glaukos Corp. (NYSE:GKOS)
DateHeadline
07/22/16 04:08 PMHow Analysts Feel About Glaukos Corp (NYSE:GKOS)? - Consumer Eagle
07/22/16 07:06 AMGlaukos Corp Just Reaches 52-Week High? - Consumer Eagle
07/21/16 07:47 AMEarnings Focus and Crowd Sourced Sentiment Review for Glaukos Corp (NYSE:GKOS) - TGP
07/20/16 05:37 PMStock Touching Overbought Territory: Glaukos Corporation (NYSE:GKOS) - Press Telegraph
07/20/16 07:05 AMEquity Roundup: Stock Performance Focus on Glaukos Corp (NYSE:GKOS) - Press Telegraph
07/20/16 07:05 AMGlaukos Corp (NYSE:GKOS): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/18/16 03:30 PMGlaukos Corporation to Release Second Quarter 2016 Financial Results after Market Close on August 1 - [Business Wire] - Glaukos Corporation , an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, plans to release second quarter 2016 financial results after the market close on Monday, August 1, 2016.
07/18/16 09:24 AMStock in Positive Territory for the Quarter: Glaukos Corporation (NYSE:GKOS) - Engelwood Daily
07/18/16 09:24 AMShare Performance Summary for: Glaukos Corporation (NYSE:GKOS) - Press Telegraph
07/18/16 09:24 AMTrading Performance and Target Watch for Glaukos Corp (NYSE:GKOS) - Press Telegraph
07/18/16 09:24 AMGlaukos Corp (NYSE:GKOS) Wall Street Analyst Recommendation Outlook - TGP
07/15/16 04:52 PMCEO of Glaukos Trades Portion of Stake in Company -
07/15/16 03:16 PMGlaukos Corporation Realized Volatility Hits Elevated Level - CML News
07/15/16 07:12 AMNew Broker Ratings For Glaukos Corporation (NYSE:GKOS) - FTSE News
07/15/16 07:12 AMGlaukos Corporation (GKOS) CFO Harrison to Retire - StreetInsider.com
07/14/16 04:22 PMGlaukos : Announces Planned Retirement of Chief Financial Officer Richard L. Harrison
07/14/16 03:58 PMGlaukos Announces Planned Retirement of Chief Financial Officer Richard L. Harrison - [at noodls] - LAGUNA HILLS, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures ...
07/14/16 03:39 PMGLAUKOS CORP Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial State -
07/14/16 07:35 AMCrowd Rating and Earnings Recap for Glaukos Corp (NYSE:GKOS) - Telanagana Press
07/13/16 04:34 PMBroker Outlook For Glaukos Corporation (NYSE:GKOS) - Fiscal Standard
07/13/16 04:34 PMGlaukos Corp (NYSE:GKOS) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/11/16 04:18 PMGlaukos Corp (NYSE:GKOS) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/11/16 04:18 PMNext Weeks Broker Price Targets For Glaukos Corporation (NYSE:GKOS) - Fiscal Standard
07/11/16 04:18 PMStock Performance Rundown on: Glaukos Corporation (NYSE:GKOS) - Press Telegraph
07/08/16 07:04 AMHow Many Glaukos Corp (NYSE:GKOS)'s Analysts Are Bullish? - Press Telegraph
07/07/16 07:04 AMWall Street Ratings and Target Price Views on Glaukos Corp (NYSE:GKOS) - Telanagana Press
07/06/16 08:55 AMGlaukos Corp (NYSE:GKOS) Company Rating and Target Watch - Telanagana Press
07/06/16 08:55 AMCan Glaukos Corp (NYSE:GKOS) Improve on the Earnings Front? - Engelwood Daily
07/06/16 08:55 AMBroker Outlook For The Week Ahead Glaukos Corporation (NYSE:GKOS) - Fiscal Standard
07/06/16 08:55 AMPerformance Recap and Target Perspective on Glaukos Corp (NYSE:GKOS) - Press Telegraph
07/04/16 09:10 AMShare Performance Recap for: Glaukos Corporation (NYSE:GKOS) - Press Telegraph
07/04/16 08:21 AM3 Top Healthcare Stocks to Buy Now -
06/30/16 07:01 AMGlaukos Corporation (NYSE:GKOS) Current Analyst Ratings - Fiscal Standard
06/30/16 07:01 AMSell-Side Recommendation & Price Target Projections on Glaukos Corp (NYSE:GKOS) - Telanagana Press
06/28/16 04:09 PMShare Update and Earnings Review for Glaukos Corp (NYSE:GKOS) - Press Telegraph
06/27/16 08:41 AMEquity Research and Technical Review on Glaukos Corp (NYSE:GKOS) - Press Telegraph
06/20/16 04:03 PMThis Weeks Broker Views For Glaukos Corporation (NYSE:GKOS) - Fiscal Standard
06/20/16 01:29 PMETF’s with exposure to Glaukos Corp. : June 20, 2016 -
06/20/16 07:43 AM3 Reasons Why Glaukos (GKOS) is a Great Momentum Stock -
06/16/16 08:35 AMShares of Glaukos Corporation (NYSE:GKOS) Sees Large Outflow of Money - Trade Calls
06/14/16 07:16 AMMoving Average Crossover Alert: Glaukos (GKOS) -
06/06/16 07:02 AMGLAUKOS CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/05/16 04:07 PMGlaukos Corp (GKOS) Receives Buy Rating from Piper Jaffray - Let Me Know About This
06/04/16 04:40 AMSizzling Healthcare Stocks Update: Glaukos Corporation (NYSE:GKOS) , C.R. Bard, Inc. (NYSE:BCR) - Is stories
06/04/16 04:40 AMGlaukos Corp (GKOS) CEO Thomas William Burns Sells 422 Shares - Let Me Know About This
06/03/16 04:31 PMGlaukos Corporation Common Stoc (NYSE:GKOS) Trading Up – Insiders Selling, Short Interest Growing
06/03/16 03:03 PMGLAUKOS CORP Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/03/16 09:38 AMCantor Fitzgerald Assumes Coverage Of Glaukos Corp With Buy, $35TP - Cantor Fitzgerald has assumed coverage of Glaukos Corp (NYSE: GKOS) with a Buy rating and $35 price target on the market potential for its iStent device in Glaucoma treatment. "Through innovation, we believe the company can not only maintain but likely expand its leading position," analyst Elemer Piros wrote in a note. The analyst estimates, in its third year on the market, iStent was used in over 70,000 procedures in 2015. iStent sales is expected to grow on its established trajectory ($100 million in sales expected in 2016). The Laguna Hills, California-based company is ...Full story available on Benzinga.com
06/03/16 04:48 AM25000 Shares of Stock are sold by Insider Selling: Glaukos Corp (GKOS) CEO - Let Me Know About This - Share Trading News25000 Shares of Stock are sold by Insider Selling: Glaukos Corp (GKOS) CEOLet Me Know About ThisGlaukos Corp logo Glaukos Corp (NYSE:GKOS) CEO Thomas William Burns sold 25,000 shares of Glaukos Corp stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $23.90, for a total transaction of $597,500.00.Glaukos Corp (GKOS) Now Covered by Cantor FitzgeraldCommunity Financial NewsGlaukos Corporation (NYSE:GKOS) Issued With 'Buy' Rating From Cantor FitzgeraldShare Trading NewsGlaukos Corporation Common Stoc (NYSE:GKOS) Trading Up - Insiders Selling, Short Interest GrowingFinance DailyMarkets.coall 7 news articles »
06/02/16 10:26 PMCantor Fitzgerald Initiates Coverage on Glaukos Corp (GKOS) - Let Me Know About This - Share Trading NewsCantor Fitzgerald Initiates Coverage on Glaukos Corp (GKOS)Let Me Know About ThisGlaukos Corp logo Investment analysts at Cantor Fitzgerald assumed coverage on shares of Glaukos Corp (NYSE:GKOS) in a research note issued to investors on Thursday. The firm set a “buy” rating and a $35.00 price target on the stock. Cantor Fitzgerald ...Glaukos Corporation (NYSE:GKOS) Sellers Covered 6.46% of Their ShortsThe PostGlaukos Corporation (NYSE:GKOS) Issued With 'Buy' Rating From Cantor FitzgeraldShare Trading NewsGlaukos Corporation Common Stoc (NYSE:GKOS) Trading Up - Insiders Selling, Short Interest GrowingFinance Dailyall 7 news articles »

Social

About Glaukos Corp.

Glaukos Corp. logoGlaukos Corporation (Glaukos) is an ophthalmic medical technology company. The Company focuses on the development and commercialization of products and procedures for the treatment of glaucoma. Glaukos has developed the micro-invasive glaucoma surgery (MIGS) for glaucoma treatment. It offers iStent, an MIGS device measuring approximately one millimeter long and approximately 0.33 millimeter wide. MIGS procedures involve the insertion of a micro-scale device from within the eye's anterior chamber through a corneal incision. The Company's micro-scale injectable therapies include pipeline products, such as the iStent Inject, the iStent Supra and iDose. The iStent Inject includes approximately two stents pre-loaded in an auto-injection inserter. The iStent Supra is designed to access an alternative drainage space within the eye. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: GKOS
  • CUSIP:
Key Metrics:
  • Previous Close: $34.11
  • 50 Day Moving Average: $29.16
  • 200 Day Moving Average: $21.43
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.11B
  • Current Year EPS Consensus Estimate: $-0.04 EPS
  • Next Year EPS Consensus Estimate: $0.09 EPS
Additional Links:
Glaukos Corp. (NYSE:GKOS) Chart for Sunday, July, 24, 2016